Personalised medicine (PM) is a cornerstone-field of healthcare, whose aim is to tailor the clinical diagnosis and treatment to the individual biochemistry of the patients and their particular molecular dysfunction.
Read moreGlySign aims at the advancement of medical glycomics, currently hampered by three main factors:
Glycan microheterogeneity, lack of quality in biomarker validation, and the complexity of the glycomics analytical technology.
The GlySign consortium is composed of three among world-class research centres and companies at the forefront of glycomics research and technology development.
Read more